[190 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 326.36 million in 2023 and expected to reach USD 365.24 million in 2024, at a CAGR 12.27% to reach USD 734.07 million by 2030.
A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.
The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region’s investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.
![Patient-Derived Xenograft/PDX Model Market Patient-Derived Xenograft/PDX Model Market](https://dmqpwgwn6vmm8.cloudfront.net/dimension/patient-derived-xenograft-pdx-model-statistics.png?t=1725740112000)
Market Dynamics
The market dynamics represent an ever-changing landscape of the Patient-Derived Xenograft/PDX Model Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Growing demand for personalized medicine
- Oncology and preclinical development
- Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
- Market Restraints
- High cost of personalized PDX model
- Market Opportunities
- Rising demand for humanized PDX Model
- Growth in pharma R&D
- Market Challenges
- Stringent guidelines regarding the ethical use of animals in cancer research
Market Segmentation Analysis
Type: Extensive use of mouse models in oncology to develop novel therapeutics
Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.
Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.
Porter’s Five Forces Analysis
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Patient-Derived Xenograft/PDX Model Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Patient-Derived Xenograft/PDX Model Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Recent Developments
Invivo Biosystems and Bioreperia Partner to Enhance Cancer Drug Testing with Advanced PDX Models
InVivo Biosystems entered into a partnership with Bioreperia to enhance their capabilities in Patient-Derived Xenograft (PDX) models. This collaboration aims to utilize Bioreperia's expertise in zebrafish models to improve the preclinical evaluation of cancer therapies. By combining their technologies, the partnership seeks to accelerate drug development processes and provide more reliable data for predicting clinical outcomes, ultimately benefiting patients through more effective treatment options. [Published On: March 14, 2024]
Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec’s 3D Spheroid Screening Platform, Kiya-Predict
Kiyatec and XenoSTART partnered to accelerate biopharmaceutical drug development through collaboration. Kiyatec's ex vivo 3D spheroid screening platform, combined with XenoSTART's Patient-Derived Xenograft (XPDX) models, aims to expedite the evaluation of therapeutic efficacy and in vivo outcomes using primary human tumors and tissues from XenoSTART's XPDX library. [Published On: June 29, 2023]
Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
The Soteria Precision Medicine Foundation and Certis Oncology Solutions have joined forces to conduct a clinical study utilizing the CertisAI platform. This study aims to predict the response of patients with KRAS-mutated cancers to different drugs. To test the therapies, orthotopic patient-derived xenografts will be utilized, and the response will be monitored using a mouse-sized MRI instrument. [Published On: June 08, 2023]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Patient-Derived Xenograft/PDX Model Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera BioLabs Inc., Inotiv, Inc. by Bioanalytical Systems, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Oncodesign Services, Pharmatest Services LLC by ValiRx Finland Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and XENTECH TECHNOLOGIES PRIVATE LIMITED.
Market Segmentation & Coverage
This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Mice Models
- Rat Models
- Tumor Type
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Hematological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Application
- Basic Cancer Research
- Biomarker Analysis
- Preclinical Drug Development
- End-User
- Academic & Research Institutions
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
This research report offers invaluable insights into various crucial aspects of the Patient-Derived Xenograft/PDX Model Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Patient-Derived Xenograft/PDX Model Market, by Type
- Patient-Derived Xenograft/PDX Model Market, by Tumor Type
- Patient-Derived Xenograft/PDX Model Market, by Application
- Patient-Derived Xenograft/PDX Model Market, by End-User
- Americas Patient-Derived Xenograft/PDX Model Market
- Asia-Pacific Patient-Derived Xenograft/PDX Model Market
- Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
- Competitive Landscape
- List of Figures [Total: 23]
- List of Tables [Total: 379]
- List of Companies Mentioned [Total: 20]
- How big is the Patient-Derived Xenograft/PDX Model Market?
- What is the Patient-Derived Xenograft/PDX Model Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?